Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough?

Ann Transl Med. 2015 Aug;3(14):202. doi: 10.3978/j.issn.2305-5839.2015.08.16.

¹ 1 Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.

No abstract available